龟井谦一郎课题组

导师简介

教育经历：

2016.9 – 2020.12 博士（硕博连读）沈阳药科大学药剂学

2012.9 – 2016.7 学士，沈阳药科大学基础药学基地班

工作经历：

2021.12 – 至今 特聘副教授，沈阳药科大学无涯创新学院

杂志任职：

1、2021 – 2022，《Acta Materia Medica》青年编委

2、2023 – 至今，《Asian Journal of Pharmaceutical Science》青年编委

荣誉奖励：

第一届药物递释青年学者奖

第一届全国博士后创新创业大赛优胜奖

沈阳市自然科学学术成果奖一等奖

执教课程：

2023级硕士研究生化学靶向药物递送，主讲，沈阳药科大学

2020级基础药学基地班生物药剂学与药物动力学实验，主讲，沈阳药科大学

主要研究方向（导师）

1、口服药物递送

2、智能药物纳米递送系统

3、应用器官芯片进行药物递送系统评价

导师主持、参与的科研项目（含科研获奖等情况）

1.搭载类脂滴前药纳米粒的仿生脂肪细胞外泌体的构建及肝癌精准靶向递送的研究，国家自然科学基金青年科学基金项目，基金编号82104109（负责人）

2.安全高效的位阻二硫键桥连的卡巴他赛脂质口服前药的研究，辽宁省自然科学基金博士科研启动项目，基金编号2022-BS-158（负责人）

3.铁死亡协同并增敏的四价铂前药自组装纳米给药系统的构建，辽宁省教育厅基础科研项目（青年人才），基金编号LJKZ0940（负责人）

4.沈阳药科大学高层次人才引进科研启动项目（负责人）

5.紫杉醇前药的初步药效学研究，企业技术服务项目，基金编号202104152（负责人）

代表性论文（导师）

1.Chutong Tian, Jingjing Guo, Gang Wang, Bingjun Sun, Kexin Na, Xuanbo Zhang, Zhuangyan Xu, Maosheng Cheng, Zhonggui He＊and Jin Sun＊. Efficient intestinal digestion and on site tumor-bioactivationare the two important determinants for chylomicron-mediated lymph-targeting triglyceride-mimetic docetaxel oral prodrugs., Advanced Science. 2019, 6, 1901810.(IF=17.521)

2.Chutong Tian,Jingjing Guo, Yifan Miao, Shunzhe Zheng, Bingjun Sun, Mengchi Sun, Qing Ye, Wenxue Liu, Shuang Zhou, Ken-ichiro Kamei＊, Zhonggui He＊and Jin Sun＊. Triglyceride-mimetic structure-gated prodrug nanoparticles for smart cancer therapy., Journal of Medicinal Chemistry. 2021, 64, 15936-15948.(IF=8.039)

3.Helin Wang, Qi Lu, Yifan Miao, Jiaxuan Song, Mingyang Zhang, Zixuan Wang, Haotian Zhang, Zhonggui He,Chutong Tian＊, Jin Sun＊. Boosting SN38-based oral chemotherapy to combinereduction-bioactivated structured lipid-mimetic prodrug with ascorbic acid., Nano Research, 2022, 15, 9092–9104.(IF=10.269)

4.Chutong Tian, Shunzhe Zheng, Xinying Liu, Ken-ichiro Kemei＊, Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system. Journal of Nanobiotechnology. 2022,20(1):338.(IF=10.2)

5.Chutong Tian, Jingjing Guo, Yifan Miao, Helin Wang, Qing Ye, Chunlin Guo, Mingyang Zhang, Zhonggui He＊, Jin Sun＊.Long chain triglyceride-lipid formulation promotes the oral absorption of the lipidic prodrugs through coincident intestinal behaviors., European Journal of Pharmaceutics and Biopharmaceutics, 2022, 176, 122-132.(IF=5.589)

6.Mingyang Zhang, Chunlin Guo, Yifan Miao, Zhonggui He, Chutong Tian＊, Jin Sun＊, Incorporating a lipophilic disulfide-bridged linoleic prodrug into a self-microemulsifying drug delivery system to facilitate oral absorption of paclitaxel., Molecular Pharmaceutics, 2023, 20, 461-472.(IF=5.364)

7.Helin Wan, Jin Sun＊,Chutong Tian＊, Zhonggui He, Probing the new strategy for the oral formulations of taxanes: changing the method with the situation., Chinese Journal of Natural Medicines, 2021,19(9):656-665.(IF=3.887)

8.Zheng, Shunzhe, Guanting Li, Jianbin Shi, Xinying Liu, Meng Li, Zhonggui He, Chutong Tian* and Ken-ichiro Kamei＊. Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy. Journal of controlled release : official journal of the Controlled Release Society 2023，361, 819–846(IF=10.8)